Skip to content

Join AMNet: An Addiction Medicine Practice-based Research and Quality Improvement Network

Your Participation Makes a Difference

AMNet is seeking addiction medicine and addiction psychiatry practices and their providers to join a practice-based research and quality improvement network. The APA, American Society of Addiction Medicine (ASAM), and Friends Research Institute created AMNet through a cooperative agreement with the National Institute on Drug Abuse (NIDA). AMNet, in collaboration with the American Academy of Addiction Psychiatry (AAAP), will address the opioid epidemic by helping practices and their providers drive quality improvement while creating a platform for future research. The network is focused on measuring and improving patient outcomes through the collection of data in PsychPRO - APA's CMS-Qualified Clinical Data Registry.

APA members can join PsychPRO at no cost. Non-APA members who participate in AMNet will gain complimentary access to PsychPRO through July 31st, 2023, after which there will be a nominal annual fee. AMNet members receive free CME clinical and research webinars to address the opioid epidemic.

If you wish to join AMNet, please complete this 5-minute survey to check your eligibility.

Take Survey Here

About AMNet

Addiction medicine and addiction psychiatry office-based practices play an important role in responding to our nation's devastating opioid epidemic. Yet, little is known about the type of patients treated in these practices, the services they receive, and their clinical outcomes. Practices often have limited opportunities to organize their patient data to inform quality improvement efforts and are rarely invited to participate in clinical research. Although much is known about opioid treatment programs (OTP) and their patients, relatively little is known about providers and the patients they treat for substance use disorders, in office-based practices, non-OTP outpatient programs, community health centers, and community mental health centers.

AMNet is supported by the National Institute on Drug Abuse (5U01DA046910), the Department of Health and Human Services, and the Patient Centered Outcomes Research Trust Fund. AMNet was created to address the nation's opioid epidemic by forging a practice-based research and quality improvement network.

AMNet participants will receive complimentary access through July 2023 to PsychPRO, APA’s CMS-Qualified Clinical Data Registry. PsychPRO offers clinician- and patient-reported outcome measures (PROMs), accessible via its clinician and patient portals, and an interactive dashboard to visualize patient-level information and facilitate data comparisons for quality improvement initiatives.

AMNet's addiction-related outcome measures in PsychPRO include:

  • Brief Addiction Monitor (BAM)
  • TAPS Tool
  • Treatment Effectiveness Assessment (TEA)
  • Short Opiate Withdrawal Scale (SOWS)
  • Clinical Opiate Withdrawal Scale (COWS)
  • Visual Analog Scale for Opioid Craving (VAS)
  • Patient Health Questionnaire (PHQ-2+1)
  • PROMIS Pain Interference

In addition, psychiatric measures available in PsychPRO include:

  • DSM-5 Cross-cutting measure
  • PHQ-9
  • GAD-7

Patients can complete these tools online, prior to their visit, or in office on tablet computers. Patient responses to measures will generate graphics, visualizing treatment progress over time.

PsychPRO's Interactive Dashboard Preview

PsychPRO offers options for patient-reported data applications that meet your practice and patient needs. The TetherAll app by TryCycle offers AMNet’s priority PROMs, while BH Works offers the full array of the AMNet and PsychPRO measures. Through the TetherAll app, patients can complete PROMs on their smartphones while BHWorks is available through a web browser.

Screenshot of the TetherAll App dashboard with the text TetherAll offers a patient app for entering the BAM, PHQ 2+1, and TEA data.

Click each image below for more dashboard views:

Screenshot of the TetherAll App dashboard with the text The corresponding TetherAll website for clinicians allows the clinician to track patient progress on the BAM, PHQ 2+1, and TEA.
Screenshot of the BH Works dashboard with the text BH Works allows for implementation of a broader measurement-based care framework in practice.
Screenshot of the BH Works dashboard with the text Access a detailed dashboard with BH Works to track patient progress with measurement-based care instruments and tools.

Who Should Participate in AMNet?

We are seeking practices and their providers including physicians, nurse practitioners, and physician assistants who prescribe any formulations of buprenorphine or naltrexone in a wide variety of outpatient settings, including:

  • Office-based Opioid Treatment Practices (OBOTs)
  • Intensive Outpatient Programs (IOPs)
  • Outpatient Programs (OPs)
  • Community Health Centers (CHCs, FQHCs)
  • Community Mental Health Centers (CMHCs)

Practices in health care and academic institutions, with or without EHRs, that regularly treat patients with opioid use and other substance use disorders are welcome. Practices can be located in urban, suburban, or rural areas. Telemedicine practices are eligible. We are currently not seeking providers in federally regulated opioid treatment programs (OTPs) because more is known about their patient outcomes than in other settings. In order for a clinician to participate, practice leadership must also agree for the practice or clinic to join.

Providers are eligible regardless of their membership status in APA, AAAP or ASAM.

Benefits of Joining AMNet

  • Real-time data to track patients' progress
  • Potential credit toward MOC Part IV Certification
  • Free CME webinars
  • Support in the use of AMNe
  • Opportunity to participate in research

Complete the Survey Today

If you wish to join AMNet, please complete this 5-minute survey to check your eligibility.

Take Survey Here

Contact Us

If you have additional questions, please contact us at [email protected].

Medical leadership for mind, brain and body.

Join Today